Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director | January 23, 2024 | January 25, 2024 |
| BIODESIX INCBDSX · Entity 6053 | Director | January 02, 2026 | January 06, 2026 |
| ELUTIA INC.ELUT · Entity 7342 | 10% owner in previous filing | March 23, 2023 | February 20, 2024 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date January 23, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Birchview Fund, LLC | 120,682 |
Reported balance
After 2024-01-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 120,682 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common Stock Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2029-01-23 | IndirectBy Birchview Fund, LLC | 100,000 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Purchase · Acquired 100,000 · Balance 100,000 F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock. F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 202,556 |
Reported balance
Holding disclosure · report date 2024-01-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 202,556 |
| Common StockSEC Table I · non-derivative | IndirectAs UGMA Custodian for minor children | 2,000 |
Reported balance
Holding disclosure · report date 2024-01-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.
F2: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
BIODESIX INC
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,804 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 6,804 · Balance 6,804 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01 | Direct | 6,354 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.
ELUTIA INC.
Report date March 23, 2023 · Filed February 20, 2024 · Amendment
Jointly reported with Birchview Capital, LP, Birchview Fund LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,615,184 |
Reported balance
After 2023-03-23 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-03-23 · Purchase · Acquired 100,000 · Balance 1,615,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,625,184 |
Reported balance
After 2023-03-23 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2023-03-23 · Purchase · Acquired 10,000 · Balance 1,625,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA"). |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,643,184 |
Reported balance
After 2023-03-24 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2023-03-24 · Purchase · Acquired 18,000 · Balance 1,643,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,645,184 |
Reported balance
After 2023-03-24 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2023-03-24 · Purchase · Acquired 2,000 · Balance 1,645,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA"). |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,655,184 |
Reported balance
After 2023-03-27 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2023-03-27 · Purchase · Acquired 10,000 · Balance 1,655,184 F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above. |
Filing footnotes · ownership attribution and instrument terms
F1: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund.
F2: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund.
F3: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA").
F4: As specified in Table I, Birchview Capital, LP advises the acquired shares in a different SMA other than the one noted above.
QuidelOrtho Corp
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,604 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 6,829 · Balance 34,604 F1: Reflects release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Exercise / conversion · Disposed 6,829 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5: The restricted stock units vested on May 29, 2026. |
| Common StockSEC Table I · non-derivative | IndirectUGMA Account | 16,630 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 16,630 F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBirchview | 38,145 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 38,145 F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Managing Partner of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F5: The restricted stock units vested on May 29, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 6,533 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Common StockSEC Table I · non-derivative | IndirectUGMA Account | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 16,630 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBirchview | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 38,145 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $53.27 · Expires 2028-04-04 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 259 · Balance 0 F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5: Vested in full. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 875 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 262 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 427 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-27 · Disposition to issuer · Disposed 85 · Balance 0 F6: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F5: Vested in full.
F6: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F7: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F8: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2023 Filed Mar 27, 2023 20:17 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 18,000 | $1.35 | $24,370.20 |
DisclosureSEC source: 0001104659-23-037129 · tm2310663-1_4seq1.xml · nonDerivative · entry 3 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,643,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| March 24, 2023 Filed Feb 20, 2024 17:27 UTC Amendment | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 2,000 | $1.35 | $2,707.80 |
DisclosureSEC source: 0001104659-24-025392 · tm246490-2_4aseq1.xml · nonDerivative · entry 4 Birchview Capital, LP · CIK 0001618205 · 10% owner in previous filing Birchview Fund LLC · CIK 0001603544 · 10% owner in previous filing Strobeck Matthew · CIK 0001377832 · 10% owner in previous filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,645,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA"). Read SEC document |
| March 24, 2023 Filed Feb 20, 2024 17:27 UTC Amendment | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 18,000 | $1.35 | $24,370.20 |
DisclosureSEC source: 0001104659-24-025392 · tm246490-2_4aseq1.xml · nonDerivative · entry 3 Birchview Capital, LP · CIK 0001618205 · 10% owner in previous filing Birchview Fund LLC · CIK 0001603544 · 10% owner in previous filing Strobeck Matthew · CIK 0001377832 · 10% owner in previous filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,643,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:17 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 10,000 | $1.49 | $14,910.00 |
DisclosureSEC source: 0001104659-23-037129 · tm2310663-1_4seq1.xml · nonDerivative · entry 2 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,625,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA"). Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:17 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 100,000 | $1.49 | $149,100.00 |
DisclosureSEC source: 0001104659-23-037129 · tm2310663-1_4seq1.xml · nonDerivative · entry 1 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,615,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| March 23, 2023 Filed Feb 20, 2024 17:27 UTC Amendment | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 10,000 | $1.49 | $14,910.00 |
DisclosureSEC source: 0001104659-24-025392 · tm246490-2_4aseq1.xml · nonDerivative · entry 2 Birchview Capital, LP · CIK 0001618205 · 10% owner in previous filing Birchview Fund LLC · CIK 0001603544 · 10% owner in previous filing Strobeck Matthew · CIK 0001377832 · 10% owner in previous filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,625,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the acquired shares in a separately managed account ("SMA"). Read SEC document |
| March 23, 2023 Filed Feb 20, 2024 17:27 UTC Amendment | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 100,000 | $1.49 | $149,100.00 |
DisclosureSEC source: 0001104659-24-025392 · tm246490-2_4aseq1.xml · nonDerivative · entry 1 Birchview Capital, LP · CIK 0001618205 · 10% owner in previous filing Birchview Fund LLC · CIK 0001603544 · 10% owner in previous filing Strobeck Matthew · CIK 0001377832 · 10% owner in previous filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,615,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:31 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 6,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000666 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,930 Underlying: Common Stock · 6,097 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 23:20 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000522 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,833 Underlying: Common Stock · 62,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period. F3 · balance_after: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service to the Issuer. Read SEC document |
| December 08, 2022 Filed Feb 14, 2023 00:01 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 4,000 | $3.79 | $15,141.20 |
DisclosureSEC source: 0001104659-23-019991 · tm236492-1_4seq1.xml · nonDerivative · entry 6 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,515,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F4 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the shares in a different SMA other than the one noted above. Read SEC document |
| December 08, 2022 Filed Feb 14, 2023 00:01 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 9,061 | $3.79 | $34,376.53 |
DisclosureSEC source: 0001104659-23-019991 · tm236492-1_4seq1.xml · nonDerivative · entry 5 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,511,184 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the shares in a separately managed account ("SMA"). Read SEC document |
| December 07, 2022 Filed Feb 14, 2023 00:01 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 34,000 | $3.58 | $121,720.00 |
DisclosureSEC source: 0001104659-23-019991 · tm236492-1_4seq1.xml · nonDerivative · entry 4 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,502,123 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F3 · ownership.nature: As specified in Table I, Birchview Capital, LP advises the shares in a separately managed account ("SMA"). Read SEC document |
| December 07, 2022 Filed Feb 14, 2023 00:01 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 10,000 | $3.58 | $35,800.00 |
DisclosureSEC source: 0001104659-23-019991 · tm236492-1_4seq1.xml · nonDerivative · entry 3 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,468,123 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| December 01, 2022 Filed Feb 14, 2023 00:01 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 40,000 | $4.75 | $190,000.00 |
DisclosureSEC source: 0001104659-23-019991 · tm236492-1_4seq1.xml · nonDerivative · entry 2 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,458,123 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 1,365,217 | $1.15 | $1,569,999.55 |
DisclosureSEC source: 0001140361-22-042597 · form4.xml · nonDerivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 2,135,076 F2 · ownership.direct: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 108,695 | $1.15 | $124,999.25 |
DisclosureSEC source: 0001140361-22-042597 · form4.xml · nonDerivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA Account Disclosed balance after: 112,213 F1 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 108,695 | $1.15 | $124,999.25 |
DisclosureSEC source: 0001140361-22-042597 · form4.xml · nonDerivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA Account Disclosed balance after: 112,213 F1 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 108,695 | $1.15 | $124,999.25 |
DisclosureSEC source: 0001140361-22-042597 · form4.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA Account Disclosed balance after: 112,213 F1 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 108,695 | $1.15 | $124,999.25 |
DisclosureSEC source: 0001140361-22-042597 · form4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA Account Disclosed balance after: 112,213 F1 · ownership.direct: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 869,565 | $1.15 | $999,999.75 |
DisclosureSEC source: 0001140361-22-042597 · form4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,415,151 Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:20 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035180 · doc4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 Underlying: Common Stock · 2,248 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 6, 2023. F2 · derivative.expiration_date: The restricted stock units vest on June 6, 2023. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Restricted Stock Units · Derivative | 75,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016064 · wf-form4_165420133707666.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,949 Underlying: Common Stock · 75,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · derivative · entry 8 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 427 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · derivative · entry 7 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 427 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · derivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · derivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 875 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 259 | $0.00 Strike: $53.27 | $0.00 |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 259 shares Expires 2028-04-04 F4 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerCommon Stock | 38,145 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Birchview Disclosed balance after: 0 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F3 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerCommon Stock | 16,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · UGMA Account Disclosed balance after: 0 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F2 · ownership.nature: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:27 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerCommon Stock | 6,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020410 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · derivative · entry 8 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85 Underlying: Common Stock · 85 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 427 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · derivative · entry 7 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427 Underlying: Common Stock · 427 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · derivative · entry 6 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · derivative · entry 5 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Underlying: Common Stock · 875 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F7 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. F8 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 259 | $0.00 Strike: $53.27 | $0.00 |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259 Underlying: Common Stock · 259 shares Expires 2028-04-04 F4 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 38,145 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · nonDerivative · entry 3 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Birchview Disclosed balance after: 38,145 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F3 · ownership.nature: The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 16,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · UGMA Account Disclosed balance after: 16,630 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F2 · ownership.nature: The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:36 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 6,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020490 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,533 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:16 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020788 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and has no expiration date. F3 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:50 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031194 · doc4.xml · derivative · entry 4 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,624 shares Expires 2022-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. Read SEC document |
| May 18, 2022 Filed May 20, 2022 19:50 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionCommon Stock | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031194 · doc4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on Form 4. Read SEC document |
| May 11, 2022 Filed Feb 14, 2023 00:01 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 200 | $5.96 | $1,192.08 |
DisclosureSEC source: 0001104659-23-019991 · tm236492-1_4seq1.xml · nonDerivative · entry 1 Birchview Capital, LP · CIK 0001618205 · 10% owner Birchview Fund LLC · CIK 0001603544 · 10% owner Strobeck Matthew · CIK 0001377832 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,418,123 F1 · ownership.nature: Matthew Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. Matthew Strobeck is the Managing Member of Birchview Partners LLC, who is the Manager of Birchview Fund, LLC ("the Fund"). Birchview Capital, LP is the investment manager of the Fund. F2 · ownership.nature: The Fund acquired the shares as specified in Table I. As investment manager of the Fund, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of the shares acquired by the Fund. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:36 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 558,659 | $1.79 | $999,999.61 |
DisclosureSEC source: 0001567619-22-008353 · doc1.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 769,859 F1 · ownership.direct: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:36 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 558,659 | $1.79 | $999,999.61 |
DisclosureSEC source: 0001567619-22-008353 · doc1.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,545,586 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 20,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-012920 · form4.xml · derivative · entry 9 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,044 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units vested in full on March 31, 2022 and had no expiration date. F2 · derivative.expiration_date: These restricted stock units vested in full on March 31, 2022 and had no expiration date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 20,044 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-012920 · form4.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 22:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 9,100 | $4.35 | $39,585.00 |
DisclosureSEC source: 0001567619-22-000277 · doc1.xml · nonDerivative · entry 2 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Capital Separately Managed Account Disclosed balance after: 19,933 F1 · ownership.direct: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The shares reported herein as held by Birchview Fund, LLC and the shares reported held by Birchview Capital Separately Managed Account were always held for each respective account, but were inadvertently reported as all being held for Birchview Fund, LLC in the Form 4 filed on November 3, 2020. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The shares reported herein as held by Birchview Fund, LLC and the shares reported held by Birchview Capital Separately Managed Account were always held for each respective account, but were inadvertently reported as all being held for Birchview Fund, LLC in the Form 4 filed on November 3, 2020. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 22:02 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 138,700 | $4.35 | $603,345.00 |
DisclosureSEC source: 0001567619-22-000277 · doc1.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund LLC Disclosed balance after: 211,200 F1 · ownership.direct: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The shares reported herein as held by Birchview Fund, LLC and the shares reported held by Birchview Capital Separately Managed Account were always held for each respective account, but were inadvertently reported as all being held for Birchview Fund, LLC in the Form 4 filed on November 3, 2020. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC and the Birchview Capital Separately Managed Account in his capacity as Managers of such entities. The shares reported herein as held by Birchview Fund, LLC and the shares reported held by Birchview Capital Separately Managed Account were always held for each respective account, but were inadvertently reported as all being held for Birchview Fund, LLC in the Form 4 filed on November 3, 2020. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 30, 2021 Filed Dec 10, 2021 16:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantCommon Stock | 19,531 | $7.68 | $149,998.08 |
DisclosureSEC source: 0001628280-21-024840 · wf-form4_163917005520386.xml · nonDerivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Birchview Fund, LLC Disclosed balance after: 206,828 F1 · shares: Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the third and final tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The third and final tranche of the offering closed on September 30, 2021. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 22:26 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 20,044 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000541 · form4.xml · derivative · entry 1 Strobeck Matthew · CIK 0001377832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,044 Underlying: Common Stock · 20,044 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units will vest in full on March 31, 2022 and have no expiration date. F2 · derivative.expiration_date: These restricted stock units will vest in full on March 31, 2022 and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.